Priothera Appoints Elisabeth Kueenburg M.D., as Chief Medical Officer

News Release – November 25, 2021 Priothera Appoints Elisabeth Kueenburg M.D., as Chief Medical Officer Dr. Kueenburg, former Clinical Development Lead at Celgene, a Bristol Myers Squibb Company, to advance clinical development of mocravimod in Acute Myeloid Leukemia patients undergoing allogeneic hematopoietic stem cell transplant DUBLIN, Nov. 25, 2021 — (Healthcare Sales & Marketing Network) — Priothera Ltd, a late-clinical stage biotechnology company pioneering the development of its S1P receptor modulator compound, mocravimod, announces the appointment of Elisabeth Kueenburg, M.D., as Chief Medical Officer. Dr. Kueenburg will lead the advancement of mocravimod into Phase 2b/3 clinical trials as a potential treatment …

Read the source article at salesandmarketingnetwork.com
2021-11-25 17:37:00